• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Xanomeline and Trospium Chloride.

作者信息

Beninger Paul

机构信息

Department of Public Health & Community Medicine, Tufts University School of Medicine, Boston, Massachussetts.

出版信息

Clin Ther. 2024 Nov;46(11):938-939. doi: 10.1016/j.clinthera.2024.10.001. Epub 2024 Oct 22.

DOI:10.1016/j.clinthera.2024.10.001
PMID:39443264
Abstract
摘要

相似文献

1
Xanomeline and Trospium Chloride.占诺美林和曲司氯铵。
Clin Ther. 2024 Nov;46(11):938-939. doi: 10.1016/j.clinthera.2024.10.001. Epub 2024 Oct 22.
2
Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial.盐酸二甲胺四环素治疗精神分裂症的疗效和安全性：一项随机临床试验。
JAMA Psychiatry. 2024 Aug 1;81(8):749-756. doi: 10.1001/jamapsychiatry.2024.0785.
3
Xanomeline and Trospium Chloride Versus Placebo for the Treatment of Schizophrenia: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed.占诺美林与氯化曲司氯铵对比安慰剂治疗精神分裂症：治疗所需人数、伤害所需人数以及受助或受伤害可能性的事后分析
Neuropsychiatr Dis Treat. 2025 Apr 5;21:761-773. doi: 10.2147/NDT.S503494. eCollection 2025.
4
The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials.占诺美林和氯化曲司氯铵对急性精神分裂症认知障碍的影响：两项3期试验汇总数据的重复研究
Am J Psychiatry. 2025 Mar 1;182(3):297-306. doi: 10.1176/appi.ajp.20240076. Epub 2024 Dec 11.
5
Xanomeline and Trospium Chloride for the Treatment of Agitation Associated With Schizophrenia: PANSS-Excited Component Results From 3 Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials.用占诺美林和氯化曲司氯铵治疗与精神分裂症相关的激越：来自3项随机、双盲、安慰剂对照的紧急试验的阳性和阴性症状量表-激越分量表结果
J Clin Psychiatry. 2025 Mar 24;86(2):24m15668. doi: 10.4088/JCP.24m15668.
6
Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the 5-Week, Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials.xanomeline与氯化曲司氯铵治疗精神分裂症的安全性和耐受性：5周随机双盲安慰剂对照EMERGENT试验的汇总结果
J Clin Psychiatry. 2025 Feb 26;86(1):24m15497. doi: 10.4088/JCP.24m15497.
7
Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials.xanomeline和氯化曲司氯铵治疗精神分裂症的疗效：三项为期5周的随机、双盲、安慰剂对照、紧急试验的汇总结果
Schizophrenia (Heidelb). 2024 Nov 2;10(1):102. doi: 10.1038/s41537-024-00525-6.
8
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.美国胆碱能毒蕈碱受体激动剂 KarXT（盐酸二甲弗林-托吡酯）治疗精神分裂症的疗效和安全性（EMERGENT-2）：一项随机、双盲、安慰剂对照、剂量灵活的 3 期临床试验结果。
Lancet. 2024 Jan 13;403(10422):160-170. doi: 10.1016/S0140-6736(23)02190-6. Epub 2023 Dec 14.
9
Xanomeline/Trospium Chloride: First Approval.占诺美林/氯化曲司氯铵：首次批准
Drugs. 2025 Jan;85(1):103-109. doi: 10.1007/s40265-024-02126-0. Epub 2024 Dec 24.
10
From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials.从理论到治疗：通过双重 M1/M4 毒蕈碱受体激动剂 xanomeline 和氯化曲司氯铵释放毒蕈碱受体激活在精神分裂症中的潜力及临床试验见解
Int J Neuropsychopharmacol. 2025 Apr 11;28(4). doi: 10.1093/ijnp/pyaf015.

引用本文的文献

1
Targeting muscarinic receptors in schizophrenia treatment: Novel antipsychotic xanomeline/trospium chloride.精神分裂症治疗中针对毒蕈碱受体：新型抗精神病药物占诺美林/氯化曲司氯铵
World J Psychiatry. 2025 Jun 19;15(6):105409. doi: 10.5498/wjp.v15.i6.105409.